左心室機能不全は、うっ血性心不全の最も一般的な原因です。症状は、体液貯留、めまい、疲労、脱力、不整脈、肺のうっ血などです。危険因子としては、高血圧、糖尿病、睡眠時無呼吸症候群、アルコール依存症、冠動脈疾患などが挙げられます。
目次
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Left Ventricular Dysfunction - Overview
Left Ventricular Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Left Ventricular Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Left Ventricular Dysfunction - Companies Involved in Therapeutics Development
BioCardia Inc
Help Therapeutics
Innopharmax Inc
Mesoblast Ltd
Quantum Genomics SA
Shanghai Life Science & Technology
Takeda Pharmaceutical Co Ltd
Valo Health LLC
Viscofan BioEngineering
Left Ventricular Dysfunction - Drug Profiles
AlloCSC-01 - Drug Profile
Product Description
Mechanism Of Action
History of Events
CardiAMP - Drug Profile
Product Description
Mechanism Of Action
History of Events
carvedilol CR - Drug Profile
Product Description
Mechanism Of Action
firibastat IR - Drug Profile
Product Description
Mechanism Of Action
History of Events
NovoCardia - Drug Profile
Product Description
Mechanism Of Action
OPL-0301 - Drug Profile
Product Description
Mechanism Of Action
rexlemestrocel-L - Drug Profile
Product Description
Mechanism Of Action
History of Events
Stem Cell Therapy for Left Ventricular Dysfunction - Drug Profile
Product Description
Mechanism Of Action
VBC-01 - Drug Profile
Product Description
Mechanism Of Action
Left Ventricular Dysfunction - Dormant Projects
Left Ventricular Dysfunction - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Left Ventricular Dysfunction, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Left Ventricular Dysfunction - Pipeline by BioCardia Inc, 2022
Left Ventricular Dysfunction - Pipeline by Help Therapeutics, 2022
Left Ventricular Dysfunction - Pipeline by Innopharmax Inc, 2022
Left Ventricular Dysfunction - Pipeline by Mesoblast Ltd, 2022
Left Ventricular Dysfunction - Pipeline by Quantum Genomics SA, 2022
Left Ventricular Dysfunction - Pipeline by Shanghai Life Science & Technology, 2022
Left Ventricular Dysfunction - Pipeline by Takeda Pharmaceutical Co Ltd, 2022
Left Ventricular Dysfunction - Pipeline by Valo Health LLC, 2022
Left Ventricular Dysfunction - Pipeline by Viscofan BioEngineering, 2022
Left Ventricular Dysfunction - Dormant Projects, 2022
Left Ventricular Dysfunction - Discontinued Products, 2022
List of Figures
Number of Products under Development for Left Ventricular Dysfunction, 2022
Number of Products under Development by Companies, 2022
Number of Products by Targets, 2022
Number of Products by Stage and Targets, 2022
Number of Products by Mechanism of Actions, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
